Microbiome Therapeutics market to be dominated by FMT Type through 2027
Growing prevalence of target
diseases is expected to drive the growth of global microbiome therapeutics market
in the forecast period, 2023-2027.
According to TechSci Research report, “Microbiome
Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2017-2027”,
the global microbiome therapeutics market
is anticipated to grow at an impressive rate in the forecast period, 2023-2027.
This can be ascribed to the potential of microbiome therapeutics in
addressing the unmet needs of existing treatment options. Additionally,
microbiome therapeutics products are a safer alternative as compared to the
conventional drug treatments. Similarly, increasing research & development
activities and funding related to microbiome therapeutics is expected to create
lucrative opportunities for the growth of global microbiome therapeutics market
during the forecast period.
However,
the stringent regulatory landscape related to therapeutic drug application
filing, approvals, clinical trials, among others can slow down the market
growth. Additionally, safety concerns associated with the use of live
biotherapeutic products can further restrict the market growth. Similarly there
are challenges related to manufacturing and storage of microbial products which
pose a major threat to the overall market growth.
Browse over XX market data Figures
spread through 110
Pages and an in-depth TOC on "MICROBIOME THERAPEUTICS MARKET"
The
global microbiome therapeutics market can be segmented into by type, by application
and region.
Based on type, the market for microbiome therapeutics
can be bifurcated into FMT and microbiome drugs. In 2021, the market was
dominated by faecal microbiota therapy (FMT). The widespread use of FMT in
the management of C. difficile infection is associated with its supremacy.
Based on application, the market can be
categorized into C. Difficile, crohn’s disease, inflammatory bowel disease,
diabetes, and others. The Clostridium
difficile infection (CDI or C. difficile) application segment is expected to
register the highest growth during the forecast period. This can be ascribed to
the widespread use of FMT in treatment of C.difficile.
Based on region, North America dominated the global
microbiome therapeutics market among Europe, Asia Pacific, South America, and
Middle East region. The region's dominance is mostly due to its
well-established research capabilities for the creation of innovative
treatments. Additionally, several initiatives taken in the region such as the
Canadian Microbiome Initiative (CMI) in Canada makes it easier to work with
partners and stakeholders. This makes it possible to concentrate research
efforts on the creation of microbial medicines.
Major operating companies operating
in global microbiome therapeutics market are:
- 4D Pharma plc
- Enterome SA
- Finch Therapeutics Group, Inc.
- Vedanta Bioscience, Inc.
- Seres Therapeutics, Inc.
- Microbiotica Limited
- Destiny Pharma plc
- Taisho Pharmaceutical Holdings Co., Ltd.
- AOBiome Therapeutics, Inc.
- Ferring Pharmaceuticals SA
DOWNLOAD FREE SAMPLE REPORT
Customers can also request
for 10% free customization on this report.
“The need for precise, reliable, safer, and effective
treatment options will drive the growth of global microbiome therapeutics
market in the coming years. Similarly, Europe will witness significant growth
in the global microbiome market on account of increasing research &
development activities, funding, and collaborations in the region.
Additionally, emerging startup companies focusing on development of microbiome therapeutic
products in the region is expected to further support the market growth. Also,
the regulatory scenario in the Europe is not as strict as in North America,
thereby supporting the market growth.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“Microbiome
Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2017-2027 Segmented By Type (FMT v/s
Microbiome Drugs), By Application (C. Difficile,
Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others)
and By Region”, has
evaluated the future growth potential of global microbiome therapeutics market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global microbiome therapeutic market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com